Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis.
Lorenz GöschlGuenter GmeinerPeter GärtnerGeorg StadlerValentin EnevMario ThevisWilhelm SchänzerSven GuddatGuro ForsdahlPublished in: Drug testing and analysis (2021)
The exogenous anabolic-androgenic steroid (AAS) stanozolol stays one of the most detected substances in professional sports. Its detection is a fundamental part of doping analysis, and the analysis of this steroid has been intensively investigated for a long time. This contribution to the detection of stanozolol doping describes for the first time the unambiguous proof for the existence of 17-epistanozolol-1'N-glucuronide and 17-epistanozolol-2'N-glucuronide in stanozolol-positive human urine samples due to the access to high-quality reference standards. Examination of excretion study samples shows large detection windows for the phase-II metabolites stanozolol-1'N-glucuronide and 17-epistanozolol-1'N-glucuronide up to 12 days and respectively up to almost 28 days. In addition, we present appropriate validation parameters for the analysis of these metabolites using a fully automatic method online solid-phase extraction (SPE) method already published before. Limits of identification (LOIs) as low as 100 pg/ml and other validation parameters like accuracy, precision, sensitivity, robustness, and linearity are given.
Keyphrases
- ms ms
- solid phase extraction
- endothelial cells
- phase ii
- loop mediated isothermal amplification
- liquid chromatography tandem mass spectrometry
- clinical trial
- real time pcr
- label free
- high performance liquid chromatography
- molecularly imprinted
- induced pluripotent stem cells
- deep learning
- simultaneous determination
- pluripotent stem cells
- randomized controlled trial
- healthcare
- clinical practice
- social media
- liquid chromatography
- high resolution
- health information
- sensitive detection
- ultra high performance liquid chromatography
- phase iii